By Finance Pulse in KeyInfo —

Sangamo Shares Plummet After Pfizer Exit

Sangamo Therapeutics shares plunged 50% as Pfizer ends collaboration on hemophilia drug, impacting biotech stocks. Discover the implications for investors.

A dramatic stock chart showcasing a steep decline in Sangamo Therapeutics' share price, with a muted
Sangamo Shares Plummet After Pfizer Exit

Sangamo Therapeutics shares lost half their value after Pfizer canceled its agreement to co-develop a hemophilia drug.

Source